CRSP (STOCKS)
CRISPR Therapeutics AG
$49.000000
+0.170000 (+0.35%)
Prev close: $48.830000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samarth Kulkarni
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,611.50M
- Employees
- 393
- P/E (TTM)
- -8.75
- P/B (TTM)
- 2.39
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
13
Buy
12
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.17 | $-1.28 | +0.1097 | +8.57% |
|
Jun 2025 (Q2)
|
$-1.29 | $-1.45 | +0.1594 | +11.00% |
|
Mar 2025 (Q1)
|
$-1.58 | $-1.28 | -0.3044 | -23.86% |
|
Dec 2024 (Q4)
|
$-0.44 | $-1.19 | +0.7517 | +63.08% |
Financial Statements
| Revenues | $38.34M |
| Benefits Costs and Expenses | $522.91M |
| Costs And Expenses | $522.91M |
| Nonoperating Income/Loss | $89.82M |
| Operating Expenses | $612.73M |
| Research and Development | $283.44M |
| Other Operating Expenses | $329.30M |
| Operating Income/Loss | -$574.40M |
| Income/Loss From Continuing Operations After Tax | -$488.30M |
| Income/Loss From Continuing Operations Before Tax | -$484.58M |
| Income Tax Expense/Benefit | $3.72M |
| Net Income/Loss | -$488.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$488.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$488.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.57 |
| Diluted Earnings Per Share | -$5.57 |
| Basic Average Shares | 264,684,810 |
| Diluted Average Shares | 264,684,810 |
| Assets | $2.25B |
| Current Assets | $1.93B |
| Noncurrent Assets | $316.22M |
| Fixed Assets | $120.83M |
| Other Non-current Assets | $195.39M |
| Liabilities | $329.33M |
| Current Liabilities | $118.96M |
| Accounts Payable | $11.80M |
| Wages | $10.15M |
| Other Current Liabilities | $97.01M |
| Noncurrent Liabilities | $210.37M |
| Equity | $1.92B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.92B |
| Liabilities And Equity | $2.25B |
| Net Cash Flow From Operating Activities | -$302.49M |
| Net Cash Flow From Operating Activities, Continuing | -$302.49M |
| Net Cash Flow From Investing Activities | $36.82M |
| Net Cash Flow From Investing Activities, Continuing | $36.82M |
| Net Cash Flow From Financing Activities | $326.49M |
| Net Cash Flow From Financing Activities, Continuing | $326.49M |
| Net Cash Flow | $60.82M |
| Net Cash Flow, Continuing | $60.82M |
| Comprehensive Income/Loss | -$496.08M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$493.88M |
| Other Comprehensive Income/Loss | -$114.22M |
| Other Comprehensive Income/Loss Attributable To Parent | -$5.58M |